Gts Securities LLC Exelixis, Inc. Call Options Transaction History

Gts Securities LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 13, 2024	BUY	$21.96 - $27.6 $81,252 - $102,120	3,700 Added 8.55%	47,000 $1.22 Million
Q2 2024 Aug 14, 2024	BUY	$20.34 - $23.73 $412,902 - $481,719	20,300 Added 88.26%	43,300 $972,000
Q1 2024 May 15, 2024	SELL	$20.17 - $23.93 $191,615 - $227,335	-9,500 Reduced 29.23%	23,000 $545,000
Q4 2023 Feb 14, 2024	BUY	$19.25 - $24.13 $411,950 - $516,382	21,400 Added 192.79%	32,500 $779,000
Q3 2023 Nov 15, 2023	BUY	$19.04 - $22.74 $211,344 - $252,413	11,100 New	11,100 $242,000

502

243M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $10.7B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

Stay updated on Gts Securities LLC with notifications on news.